ANSELL LIMITED — Capital/Financing Update 2011

Aug 16, 2011

==> picture [51 x 48] intentionally omitted <==

==> picture [52 x 48] intentionally omitted <==

==> picture [51 x 48] intentionally omitted <==

==> picture [52 x 48] intentionally omitted <==

==> picture [52 x 48] intentionally omitted <==

==> picture [51 x 48] intentionally omitted <==

==> picture [52 x 48] intentionally omitted <==

==> picture [35 x 71] intentionally omitted <==

==> picture [42 x 71] intentionally omitted <==

==> picture [51 x 48] intentionally omitted <==

==> picture [52 x 48] intentionally omitted <==

==> picture [51 x 48] intentionally omitted <==

==> picture [52 x 48] intentionally omitted <==

==> picture [52 x 48] intentionally omitted <==

==> picture [51 x 48] intentionally omitted <==

==> picture [52 x 48] intentionally omitted <==

==> picture [35 x 71] intentionally omitted <==

==> picture [42 x 71] intentionally omitted <==

==> picture [51 x 47] intentionally omitted <==

==> picture [52 x 47] intentionally omitted <==

==> picture [51 x 47] intentionally omitted <==

==> picture [52 x 47] intentionally omitted <==

==> picture [52 x 47] intentionally omitted <==

==> picture [51 x 47] intentionally omitted <==

==> picture [52 x 47] intentionally omitted <==

Starpharma terminates Reckitt Agreement and signs with Ansell

Melbourne, Australia; 17 August 2011 – Starpharma Holdin g s Limited ( A SX:SPL, OTCQ X :SPHRY) t oday anno u nced two important d e velopmen t s in relatio n to the comm e rcialisation of its Viva G el[®] -coate d condom.

Starpharma terminates condom coating agreement with Reckitt Benckiser

The fir s t of these i s that, due t o the failur e to achiev e satisfact o ry progres s in relation to certain commerci a lisation mil e stones for the VivaG e l[®] -coated c ondom, St a rpharma’s Board has taken the decision to ter m inate the L icence gra n ted to Re c kitt Bencki s er (RB; formerly ® SSL In t ernational p lc) to com m ercialise the VivaGel -coated c o ndom and all of RB’s rights to the pro d uct, effect i ve immedi a tely. Starpharma is e x tremely di s appointed t o have to take this action b ut after full considera t ion of the s ituation, Di r ectors and Managem e nt believe it to be the be s t course of action to e n sure timel y commercialisation a n d maximis e returns for the VivaG e l[®] -coated condom.

Starpharma executes condom coating agreement with Ansell

The se c ond devel o pment is t h at Starph a rma has to d ay execut e d a Licen c e Agreem e nt with Ansell L imited (ASX:ANN) gi v ing Ansell m arketing rights to the VivaGel[®] - c oated con d om. The Agreement c o vers mark e ting rights t o the coat e d condom in countrie s which ex c lude Japan a nd a num b er of Asian markets.

Under t he agreem e nt Ansell w ill pay Sta r pharma ro y alties on sales of Viv a Gel[®] -coat e d condo m s and will s upport registration and other co m mercialisation costs. A nsell is al s o respon s ible for m a nufacturin g the VivaG e l[®] -coated c ondom and marketin g of the pro d uct, ® which w ill include t he VivaGe l brand to g ether with t he respective Ansell b rand.

In com m enting on the deal with Ansell, S tarpharma’s CEO, Ja c kie Fairley said:

“We ar e very plea s ed to be working with Ansell as a commerci a l partner f o r the Viva G el[®] - coated condom. Ansell is ran k ed numbe r two globa l ly in terms of condom sales, mar k eting leading brands including Life s tyles[®] , ZE R O[®] and th e highly su c cessful SKYN[®] brand . It has a leadi n g market p osition in t h e rapidly expanding A sia Pacific and South A merican m arkets and in A ustralia with around 7 0% marke t share.”

Whilst t hese developments mean that th e first appr o val of VivaGel[®] -coate d condoms will not occur i n 2011 as o riginally forecast, Star p harma’s B oard is co n fident that t he two co m mercial partner s hips now in place - with Okamot o Industrie s and Ansell Limited w i ll deliver ti m ely comm e rcialisation and maxi m ise returns for the Viv a Gel[®] -coat e d condom . Starphar m a now expect s first mark e ting appro v als to occ u r in CY 20 1 2.

Ansell’ s total sale s for the FY 2011 were US$1.2bill i on, up 11 % over last y ear. The S exual Wellne s s global b u siness uni t achieved s ales growth of 18% globally. Re c ent innov a tions

such a s the polyis o prene con d om, SKY N ® have un d erpinned s trong sale s growth, particularly in the U S, China, India, Brazil, ANZ, an d Poland.[[1]]

In com m enting on the deal A n sell’s President & Ge n eral Mana g er - Sexu a l Wellness Global Busine s s Unit, Pe t er Carroll s aid:

“Ansell is very excited about p artnering w ith Starph a rma on th e applicatio n of their Vi v aGel[®] produc t with our l e ading “lifestyles” prod u cts. The V ivaGel[®] -coated cond o m offers A n sell an innovative and diff e rentiated p roduct an d it fits well w ith Ansell’s focus on new produ c ts as part of o ur growth strategy. B u ilding on o ur success with the S K YN[®] rang e we see VivaGel[®] as fittin g well withi n Ansell’s i n novative product fra m ework”.

Starph a rma’s CE O Jackie Fairley added:

“Starpharma remains fully co m mitted to t he comme r cialisation of the Viva G el[®] -coate d condo m and belie v e this is th e right course of actio n for the pr o duct. We l o ok forwar d to workin g with both o f our part n ers Ansell a nd Okam o to to launc h this inno v ative prod u ct into the bra n ded cond o m market. ”

The gl o bal brande d condom m arket has been estimated to be w orth US $1.1billion$1.6billion and gr o wing at ar o und 4-5% a nnually.[[2]]

[1] Ansell Annual Report 2010 and Full Year R esults 2011 [2] Condoms - A global strate g ic business re p ort 2006, 2010; Annual Repor t s and industry d ata.

==> picture [35 x 25] intentionally omitted <==

==> picture [51 x 25] intentionally omitted <==

==> picture [52 x 25] intentionally omitted <==

==> picture [51 x 25] intentionally omitted <==

==> picture [52 x 25] intentionally omitted <==

==> picture [52 x 25] intentionally omitted <==

==> picture [51 x 25] intentionally omitted <==

==> picture [52 x 25] intentionally omitted <==

==> picture [38 x 25] intentionally omitted <==

Starpharma Holdin g s Limited ( A SX:SPL, O T CQX:SPH R Y) is a wo r ld leader i n the develo p ment of dendrimer technolo g y for phar m aceutical, life-science a n d other ap p lications. S P L has two o perating companies, Starpharma Pty Ltd in Melbourn e , Australia a nd DNT, In c in the US A . Products b ased on SPL’s d endrimer t e chnology a r e already o n the mar k et in the f o rm of diag n ostic elem e nts and laborat o ry reagents t hrough lice n ce arrange m ents with p a rtners including Sieme n s and Merc k KGaA.

The Company’s le a d pharmac e utical deve l opment pr o duct is Viv a Gel[®] (SPL 7 013 Gel), a vaginal microbi c ide designed to prevent the transmi s sion of STI s , including HIV, genital herpes and bacterial vaginos i s. Starpha r ma has a l i cence agre e ment with A nsell Limit e d to devel o p a VivaGe l ®-coated condom, and a licence agreement with Okamoto Indu s tries Inc in relation to t he VivaGel ® -coated condom for the Ja p anese mar k et. Okamoto is the m a rket leader for condoms sold in J a pan, the world’s s econd larg e st condom m arket.

Starpharma also ha s agreemen t s in place w ith Lilly, El a nco, Stiefel Laboratorie s (a GSK C o mpany), and Siemens Healt h care as well as many r esearch collaborations w ith some o f the world’ s leading organis a tions in the fields of pharmaceutical s , drug deliv e ry, cosmeti c s and agro c hemicals.

A dend r imer is a ty p e of precis e ly-defined, branched n a noparticle. Dendrimers have appli c ations in the medical, electro n ics, chemic a ls and mat e rials industries.

ABOU T ANSELL LI M ITED (ASX:A N N)

==> picture [52 x 13] intentionally omitted <==

==> picture [52 x 13] intentionally omitted <==

==> picture [51 x 13] intentionally omitted <==

==> picture [52 x 13] intentionally omitted <==

==> picture [38 x 13] intentionally omitted <==

Ansell i s a world l e ader in pro v iding supe r ior health a nd safety protection solutions that enhance human well being. With operations in the North Ame r ica, Latin A merica, EM E A and Asi a , Ansell employ s more than 10,000 peo p le worldwid e and holds leading posi t ions in the i n dustrial an d medical gloves m arket, as w ell as in the sexual health and well being categ o ry worldwide. Ansell o p erates in four m a in business segments: Medical Solutions, Ind u strial Soluti o ns, New V erticals, an d Sexual Wellness. Informati o n on Ansell and its prod u cts can be f ound at ww w .ansell.co m .

American Depositary Receipts (ADRs): Starpharma’s AD R s trade under the code SPHRY (CUSI P number 8555631 0 2). Each S tarpharma A DR is equiv a lent to 10 ordinary shar e s of Starph a rma as trad e d on the Australian Securities Exchange (A S X). Starph a rma’s ADRs are listed on Internation a l OTCQX, a premium market ti e r in the U.S. for internatio n al exchange- l isted compa n ies.

Forward Looking Statements

This document contains certain fo r ward-looking statements, relating to Starpharma’s business, whi c h can be identified by the use o f forward-lo o king terminol o gy such as “promising”, “plans”, “antic i pated”, “will”, “project”, “believe” , “forecast”, “ e xpected”, “e s timated”, “tar g eting”, “aimi n g”, “set to”, “ p otential”, “seeking to”, “go a l”, “could provide”, “intends”, “i s being devel o ped”, “could be”, “on trac k ”, or similar e xpressions, or by express or implied discussi o ns regarding potential fili n gs or marketing approval s , or potential future sales of product c a ndidates. Such for w ard-looking statements i n volve known and unkno w n risks, uncertainties and other factors that may cause a c tual results t o be materiall y different fro m any future r e sults, perfor m ance or achi e vements ex p ressed or implied b y such state m ents. There can be no a s surance that any existing o r future regulatory filings w ill satisfy the FDA’ s and other h e alth authoriti e s’ requirements regarding any one or m o re product c a ndidates nor can there be any a s surance tha t such produc t candidates w ill be approv e d by any he a lth authoritie s for sale in any market or that t h ey will reac h any partic u lar level of s ales. In particular, mana g ement’s exp e ctations reg a rding the approval and commer c ialization of the product c a ndidates cou l d be affected by, among o t her things, u n expected clinical t r ial results, i n cluding addi t ional analysi s of existing clinical data, and new cli n ical data; u n expected regulatory actions or d elays, or gov e rnment regulation genera l ly; our ability to obtain or m aintain pate n t or other proprietary intellectua l property pr o tection; competition in g e neral; gover n ment, indus t ry, and gen e ral public pricing p ressures; an d additional f actors that i n volve signifi c ant risks an d uncertainti e s about our products, product c andidates, fi n ancial result s and business prospects. S hould one o r more of the s e risks or un c ertainties materiali z e, or should underlying a ssumptions p rove incorre c t, actual res u lts may var y materially f r om those describe d herein as a n ticipated, be l ieved, estim a ted or expec t ed. Starphar m a is providing this inform a tion as of the date of this doc u ment and d o es not assume any obli g ation to update any forward-looking statements containe d in this docu m ent as a res u lt of new information, futur e events or d e velopments o r otherwise.

==> picture [35 x 94] intentionally omitted <==

==> picture [51 x 48] intentionally omitted <==

==> picture [52 x 48] intentionally omitted <==

==> picture [51 x 48] intentionally omitted <==

==> picture [52 x 48] intentionally omitted <==

==> picture [52 x 48] intentionally omitted <==

==> picture [51 x 48] intentionally omitted <==

==> picture [52 x 48] intentionally omitted <==

==> picture [38 x 48] intentionally omitted <==

==> picture [51 x 47] intentionally omitted <==

==> picture [52 x 47] intentionally omitted <==

==> picture [51 x 47] intentionally omitted <==

==> picture [52 x 47] intentionally omitted <==

==> picture [52 x 47] intentionally omitted <==

==> picture [51 x 47] intentionally omitted <==

==> picture [52 x 47] intentionally omitted <==

==> picture [38 x 47] intentionally omitted <==